[Image] Bertis Bio USA 2024 Presentation Schedule

The first company introduction presentation will take place on June 3rd, local time (PST), at 6:00 PM at the Aquillius Innovation Hub as part of the 'Seoul Bio Forum,' organized by Invest Seoul, Seoul BioHub, and others. The event is dedicated to fostering networking opportunities among Korean enterprises engaged in BIO USA 2024, venture capital firms seeking U.S. market entry and investment, and bio-tech and legal entities possessing the requisite expertise for U.S. expansion. Bertis will showcase its proteomics-based early diagnosis solution technology and outline its growth strategy.

On the third day of the event, June 5th at 2:30 PM, Bertis will conduct a Company Presentation session at Hall A Company Presentation Theater4. During this session, Bertis will introduce its successfully commercialized proteomics-based early diagnostic blood test pipeline and its mass spectrometry-based omics analysis service PASS (Pan-omics Analysis Service & Solution) to global bio-pharmaceutical companies. The company aims to explore opportunities for overseas business partnerships and collaborations through this session.

Seung-man Han, the CEO of Bertis, stated, "Proteomics will play a crucial role in addressing major challenges facing the medical and healthcare sectors worldwide, enabling precision medicine. Through this event, Bertis aims to share the excellence and commercial viability of our core technology. We also strive to secure business cooperation opportunities to accelerate the introduction of proteomics-based technologies and products into clinical practice."

Furthermore, Bertis leads technological innovation in the field of clinical proteomics by leveraging ProteoID, its core technology framework spanning protein data analysis to product and service commercialization. In 2019, Bertis achieved the world's first commercialization of a proteomics-based early diagnostic blood test for breast cancer, MASTOCHECK®, in both domestic and Singaporean markets, conducting a cumulative total of 170,000 tests in South Korea. Currently, they are advancing the development of early diagnostic tests for pancreatic and ovarian cancers as part of their pipeline expansion.